Breast Cancer | Specialty

Guidelines and Approaches to HER2 Testing for Breast Cancer

June 30th 2020

FDA Approves Fixed-Dose Pertuzumab/Trastuzumab Combo in HER2+ Breast Cancer

June 29th 2020

The FDA has approved a fixed-dose combination of pertuzumab (Perjeta) and trastuzumab (Herceptin) with hyaluronidase, administered via subcutaneous injection in combination with intravenous chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.

Nivolumab/Ipilimumab Combo Shows Promise in Metaplastic Breast Cancer

June 26th 2020

Sylvia Adams, MD, discusses the cohort 36 findings of the DART trial in metaplastic breast cancer and the evolution of immunotherapy, specifically in this rare breast cancer subtype.

Double PIK3CA Mutations in Breast Cancer Increase Sensitivity to PI3Kα Inhibition

June 24th 2020

Patients with breast cancer who harbor multiple PIK3A-mutant tumors achieved a higher clinical benefit from PI3Kα inhibition compared with single mutant tumors according to response analysis data from the SANDPIPER trial.

Neoadjuvant Atezolizumab/Chemo Combo Improves pCR in Early TNBC

June 18th 2020

The combination of atezolizumab and nab-paclitaxel, followed by doxorubicin and cyclophosphamide, demonstrated a statistically significant and clinically meaningful improvement in pathological complete response compared with placebo plus chemotherapy as a neoadjuvant treatment for patients with early triple-negative breast cancer, regardless of PD-L1 expression.

Tucatinib Combo Slated as New Third-Line Standard in HER2+ Breast Cancer With CNS Metastases

June 17th 2020

Nancy U. Lin, MD, discusses the updated data from the HER2CLIMB trial and underscored the need for future clinical trials that include patients with brain metastases to help fill the unmet need in the HER2-positive space.

Abemaciclib Significantly Improves iDFS in High-Risk HR+ Early Breast Cancer

June 16th 2020

Abemaciclib in combination with standard adjuvant endocrine therapy demonstrated a significant improvement in invasive disease-free survival compared with endocrine therapy alone in patients with high-risk, HR-positive, HER2-negative early breast cancer.

Dr. Graff on Future Research With Immunotherapy in Breast Cancer

June 15th 2020

Stephanie L. Graff, MD, discusses future research with immunotherapy in breast cancer.

Trastuzumab Deruxtecan Is Active in HER2 Low-Expressing Breast Cancer

June 10th 2020

The novel HER2-directed antibody-drug conjugate trastuzumab deruxtecan-nxki demonstrated promising antitumor activity in patients with heavily pretreated, HER2 low-expressing advanced or metastatic breast cancer.

Live Broadcast on Metastatic Triple-Negative Breast Cancer

June 10th 2020

Join us for a live broadcast on Wednesday, June 17, 2020 at 5 PM PST and 8 PM PST.

Dr. Cortes on Updated PFS Data From KEYNOTE-355 in PD-L1-High TNBC

June 9th 2020

Javier Cortes, MD, PhD, discusses updated progression-free survival data from the phase 3 KEYNOTE-355 study with pembrolizumab plus chemotherapy in previously untreated patients with locally recurrent, inoperable or metastatic triple-negative breast cancer.

Dr. Tolaney on CNS Recurrence in HER2+ Breast Cancer

June 9th 2020

Sara M. Tolaney, MD, MPH, discusses the unmet need with regard to effectively preventing central nervous system recurrence in HER2-positive breast cancer.

Dr. Gwin on the Mechanism of Action of Alpha-TEA in HER2-Positive Metastatic Breast Cancer

June 5th 2020

William R. Gwin III, MD, discusses the mechanism of action of alpha-tocopheryloxyacetic acid in HER2-positive metastatic breast cancer.

Dr. Favret on Extending Survival and Improving Outcomes in Breast Cancer

June 4th 2020

Anne Favret, MD, discusses the importance of clinical trials in the breast cancer space.

Sacituzumab Govitecan Becomes First ADC Approved for TNBC

June 3rd 2020

Aditya Bardia, MD, MPH, discusses how the antibody-drug conjugate sacituzumab govitecan-hziy can address the unmet need in metastatic triple-negative breast cancer and the toxicities seen with the therapy.

Addition of Veliparib to Cisplatin Significantly Improves PFS in BRCA-Like Advanced TNBC

June 2nd 2020

The addition of veliparib to cisplatin resulted in a significant improvement in progression-free survival and a trend toward improved overall survival in patients with BRCA-like triple-negative breast cancer.

Palbociclib Falls Short in Phase 3 Early Breast Cancer Trial

June 1st 2020

The phase 3 PALLAS trial exploring palbociclib (Ibrance) in patients with HR-positive, HER2-negative early breast cancer is unlikely to demonstrate a statistically significant improvement in the study’s primary end point of invasive disease-free survival.

Alpelisib Nears EU Approval for PIK3CA+ Breast Cancer

June 1st 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the PI3K inhibitor alpelisib for use in combination with fulvestrant as treatment for patients with breast cancer.

Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer

May 31st 2020

Pyrotinib plus capecitabine achieved a better progression-free survival than lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and chemotherapy.

Dr. Lin on Updated Findings of HER2CLIMB Study in HER2+ Breast Cancer Brain Mets

May 30th 2020

Nancy U. Lin, MD, discusses updated findings from the phase 2 HER2CLIMB study in patients with HER2-positive metastatic breast cancer with brain metastases.